Associate Professor Tam Nguyen has over 20 years of working in the healthcare, health & medical research environment including tertiary teaching hospitals and research institute across Australia. Tam is the Deputy Director of Research at St Vincent’s Hospital Melbourne, one of the largest tertiary teaching and research hospitals in Melbourne. He holds academic appointments with the Melbourne Medical School and Monash Medical and sit on the Investment Committee of Horizon3Biote Fund. Tam also invest and advise early stage biotech and medtech companies across Australia and Singapore.
Jaime McCoy was appointed General Manager of Gilead Sciences in Australia and New Zealand in 2019. At Gilead, Ms McCoy is responsible for all aspects of the Australian business including its liver, HIV, oncology, emerging viruses and cell therapy business units. She led Gilead ANZ’s innovative pandemic response, working in close partnership with government and healthcare professionals, to secure registration of the first approved treatment for COVID-19. She also led Gilead ANZ’s successful priority review and government funding of the first treatment in Australia for metastatic triple negative breast cancer.
Ms McCoy has worked in the pharmaceutical and biotechnology industry for more than 20 years across Asia, Europe and Australia and has enjoyed a meaningful career in a sector she is deeply committed to, and that aligns with her personal mission of improving the lives of patients and their families.
Hugh is CEO of Kinoxis Therapeutics, a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Hugh has over 25 years’ experience in the pharma/biotech industries, and has successfully led development programs through to FDA approval and completed corporate transactions with global pharmaceutical companies. Hugh is also a non-executive director of Dimerix Limited and Servatus Limited.
Ms Chong has 24 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in four marketed oncology products. She was previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.
Jon has been CEO of Neuren since May 2020. Since joining as CFO in 2013, he has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included the IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years with international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.
